SynBac
Traditional process scale up using baculovirus is notoriously problematic, with yields dropping progressively during scale up. SynBac™ are minimized baculoviral genomes created using modern synthetic biology techniques. The SynBac™ project aims to transform fermenter-scale baculoviral production of drug targets, and manufacturing scale production of biopharmaceuticals by creating minimal baculoviral genomes displaying exceptional DNA stability. In addition to improved DNA stability, our minimized genomes form the starting point for applications that require large DNA cargo delivery to mammalian cells, primary cells, or organs.
17th Oct 2020
Recent Posts
-
Reflections on Our Experience at the Vatican Longevity Summit
On March 24, 2025, the Vatican opened its doors to a remarkable gathering of scientists, ethicists, …25th Mar 2025 -
Gentaur : The Leading Distributor of Applied Biological Materials (ABM) in Belgium and Europe
Driving Scientific Innovation with ABM's Cutting-Edge Products Gentaur has long been the trusted dis …19th Mar 2025 -
From SCSOmics 2024 to 2025 !
From SCSOmics 2024 to 2025: Single-Cell Passion Ignites Again ! We’re still buzzing from Sin …17th Mar 2025